Epitope-specific regulation. I. Carrier-specific induction of suppression for IgG anti-hapten antibody responses by Herzenberg, LA & Tokuhisa, T
EPITOPE-SPECIFIC  REGULATION 
I.  Carrier-specific Induction  of Suppression 
for IgG Anti-Hapten  Antibody  Responses* 
BY  LEONORE  A.  HERZENBERG  AND TAKESHI  TOKUHISA~ 
From the Department of Genetics, Stanford University School of Medicine, Stanford, Cahfornia 94305 
In  this series of publications  (1) 1 we defined  the properties of an  epitope-specific 
regulatory system  (2-4)  that  operates centrally to control the amount,  affinity, and 
isotype/allotype composition of antibody responses to individual epitopes on complex 
antigens. This system, which has gone unrecognized as such despite more than  l0 yr 
of intensive study of the cells and cell interactions controlling antibody production, 
provides a  versatile Igh-restricted effector mechanism that selectively shapes primary 
and subsequent antibody responses to a  given epitope according to the dictates of the 
regulatory environment when the epitope is first introduced. 
For example, we show  that  priming young  allotype-suppressed mice  induces  the 
epitope-specific  system  to  selectively  suppress  allotype-marked  (Igh-lb)  antibody 
responses  to  all epitopes on  the priming antigen)  This  suppression  then  persists so 
that  the  animals  fail  to  produce  Igh-lb  responses  to  the  priming-antigen  epitopes 
when reimmunized after the onset of the characteristic midlife remission from allotype 
suppression  (during  which  de  novo  immunizations  induce  normal  Igh-lb  antibody 
responses). 
Immunizing  carrier-primed mice  with  a  "new"  epitope  coupled  to  the  priming 
carrier  also  induces  the  epitope-specific system  to  suppress  antibody  production; 
however, under these conditions, antibody responses to the newly introduced epitope 
are selectively suppressed, and anti-carrier responses proceed normally (2-4). 2 Studies 
presented here trace the induction of this suppression to the in situ activity of carrier- 
specific suppressor T  cells (CTs) 3 and  show  further  that  the epitope-specific system 
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We previously called this regulatory mechanism "hapten-specific," using the term "hapten" in its more 
general sense (synonymous with epitope)  to indicate  a relatively small structure  that induces antibody 
production  when presented on a larger (carrier) molecule. This term, however, is also commonly used to 
distinguish artificially added structures  such as the dinitrophenyl  phenyl group  (DNP) from the native 
epitopes on a carrier molecule (antigen). Therefore, to avoid ambiguity, we have now substituted the term 
"epaitnpe-specific"  for the previous nomenclature. 
' Abbreviations used in  this paper."  CTs,  carrier-specific suppressor T  cell; DNP  (or D),  dinitrophenyl 
hapten;  TNP,  trinitrophenyl hapten;  PC,  phosphoryl-choline  hapten;  CGG  (or C),  chicken  gamma 
globulin; KLH (or K), keyhole limpet hemocyanin; TGAL ((T,G)-A--L), poly-l-(tyrosine,  glutamie acid)- 
poly-m.-alanine-poly-L-lysine; RIA, solid-phase radioimmune  assay. 
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constitutes  the  major,  if not  only,  effector  mechanism  through  which  CTs  control 
antibody production. 
That  is,  we define  the  characteristics  of the  epitope-specific  suppression  in  these 
"carrier/hapten-carrier"  immunized  animals,  show  that  it  is  induced  by a  carrier- 
specific  mechanism,  and  then  show  that  "classical"  CTs  generated  according  to 
protocols originated by Tada and colleagues (4, 5) duplicate this function in adoptive 
recipients.  Thus, we demonstrate  directly that CTs regulate antibody production by 
inducing typical epitope-specific suppression (rather than by depleting carrier-specific 
help, as previously believed)  and thereby identify an in situ regulatory role for these 
cells. 
In  addition,  we  present  (summarized)  data  from  an  extensive  series  of in  situ 
immunization  experiments  indicating  that  the  carrier-specific  and  epitope-specific 
mechanisms described here represent general regulatory processes. For example, these 
studies  show that  epitope-specific  suppression  can be induced with  diverse antigens 
administered  under widely different  immunization  conditions  in a  variety of mouse 
strains. 
We discuss the relationship of these suppressive mechanisms to the overall regulation 
of antibody responses in the second publication in this series (1), which shows that the 
individually specific, IgH-restricted elements that comprise the epitope-specific system 
can be induced either  to support  or suppress antibody production and then  tend to 
maintain  themselves  as  initially  induced  during  subsequent  immunizations.  This 
novel  bistable  regulatory capability provides the  key to understanding  how carrier- 
primed animals can produce normal primary and secondary IgG anti-carrier antibody 
responses, even though they have CTs that induce suppression for antibody responses 
to new determinants  presented on the carrier. 
Materials  and Methods 
Mice.  Unless otherwise indicated,  BALB/c or (BALB/c ×  SJL/JHz)F1 mice bred  in our 
colony were used between 2 and 5 mo of age. 
Antigens.  Keyhole limpet hemocyanin (KLH) (Pacific Bio-Marine Laboratories Inc., Venice, 
CA),  chicken gamma globulin  (CGG)  (United  States  Biochemical Corp., Cleveland,  Ohio), 
and  bovine serum  albumin  (BSA)  were used;  DNPI I-KLH, DNP8-CGG,  DNP5-BSA, and 
DNP-41-BSA were prepared as previously described (7-8). 
Antibodies.  Analyses of  antibody levels in serum were performed using monoclonal antibodies 
to Igh-la [Igh(la)8.3], Igh-lb [Igh(lb)5.7], Igh-4a [Igh(4a)10.9], and Igh-4b [Igh(4b)12.8], and 
with affinity-purified rabbit anti-IgM and IgG3 reagents (7-9). 
Serum Antibody  Levels and Affinity.  The solid-phase  radioimmune  assays  (RIA)  have  been 
described in detail (7, 8). The amount of antibody in a test sample is determined by comparison 
with the antibody bound from a "standard" secondary response antiserum. Antibody levels are 
expressed as units (percentage of standard) per ml test serum or/~g antibody per ml, depending 
on whether/.tg per ml values have been determined for the standard serum, e.g., the anti-DNP 
standard serum used here has 100/tg/ml of Igh-lb anti-DNP. 
Mean antibody responses shown represent the arithmetic average of the individual responses 
of four animals (generally) per experimental group. Data are presented for responses measured 
at 2 wk after the last indicated antigenic stimulation because these responses are representative 
of the serum antibody levels and affinities that persist  for at least an additional 4 wk in virtually 
all animals tested. 
Average affinities shown for anti-DNP responses were determined from the ratio of antibody 
bound to DNP5-BSA and DNP41-BSA (at room temperature). We have shown previously that 
this ratio is proportional to log Ka (affinity)  (7). In the studies presented here, affinity values 
were determined  from the equation  Ka =  1.18 X  (106) (ea'75r),  where  r  is the amount  of a 1732  CARRIER-SPECIFIC  INDUCTION  OF  SUPPRESSION 
particular  isotype or allotype  bound  to DNP5-BSA)  per the amount  bound  to DNP41-BSA  at 
a  given  dilution  (see  ref.  7).  This  equation  is  defined  from  the  binding  ratios  obtained  with 
purified  anti-DNP  hybridomas  or myeloma  antibodies  of known  affinity. 
Immunizations.  Unless  otherwise  declared,  animals  were  immunized  with  100  #g  of  the 
indicated  carrier  protein  or  hapten-carrier  conjugate  on  alum,  regardless  of  whether  the 
immunization  represented  the first  (primary)  stimulation  or a  subsequent  stimulation  with  the 
same  or a  different  antigen. 
Cell  Transfer Studies.  The  general  methods  used  here  for  preparing  and  injecting  cell 
suspensions have been described  previously  (7). Details for individual  experiments  are presented 
with  each  figure and  table. 
Results  and Discussion 
In the analysis that follows, we measure the amount, affinity, and isotype compo- 
sition  of  anti-hapten  and  anti-carrier  antibody  responses  occurring  in  individual 
animals exposed to sequential immunizations with carrier proteins and hapten-carrier 
conjugates. 
Carrier/Hapten-Carrier Immunization Induces Suppression for  IgG Anti-Hapten Antibody 
Production.  Data  in  Table I  show  that  priming with  either of two commonly used 
carriers markedly and persistently impairs IgG antibody production to a new epitope 
(the DNP hapten) subsequently presented on the priming carrier. For example, anti- 
DNP  responses  in animals  immunized  first  with  KLH  and  then  twice  with  DNP- 
KLH  (100 #g  each  antigen  on alum)  are  roughly  10-fold  lower  in  magnitude  and 
100-fold lower in affinity than the normal secondary anti-DNP responses obtained in 
TABLE  I 
Anti-hapten Antibody Production Is Specifically Suppressed in Carrier/Hapten-Carrier-immunized Mice 
Immunizations  In situ IgG2a antibody responses* 
Anti-DNP  Anti-carrier 
Carrier  Primary  Secondary 
DNP  DNP  Primary  Secondary  Anti-  Anti- 
KLH  CGG 
btg/ml  Ka$  p,g/ml  Ka$  units  units 
--  DNP-KLtt  35  (5)  --  --  15  -- 
--  DNP-KLH  DNP-KLH  --  --  120  (300)  130  -- 
--  DNP-KLH  DNP-CGG  --  --  60  (100)  --  9 
--  DNP-CGG  13  (1)  --  --  --  11 
--  DNP-CGG  DNP-CGG  --  --  85  (400)  --  100 
KLH  ....  20  -- 
KLH  DNP-CGG  20  (2)  --  --  --  21 
KLH  DNP-KLH  5  (<0.3)  --  --  17O  -- 
KLH  DNP-KLH  DNP-KLH  --  --  9  (0.5)  370  -- 
KLH  DNP-KLH  DNP-CGG  --  6  (<0.3)  8 
CGG  .....  [ 2 
CGG  DNP-KLH  15  (0.6)  --  --  ND§  -- 
CGG  DNP-CGG  5  (<0.3)  --  --  --  70 
CGG  DNP-CGG  DNP-CGG  --  --  7  (2)  --  210 
* BALB/c ×  SJL mice were injected intraperitoneally with 100 #g of the indicated antigen on alum at ~6- 
wk intervals. 
* Serum  antibody  levels were  measured  by  RIA  2  wk  after  last  immunization.  Anti-carrier  antibody 
expressed as percentage of antibody in a  "standard" secondary response serum pool. 
$ Ka M -~  X  106 measured by RIA (8). 
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control  animals just  immunized  twice  with  DNP-KLH.  Similarly,  IgG  anti-DNP 
antibody responses remain at or below primary level in CGG/DNP-CGG/DNP-CGG- 
immunized animals. The IgG2a responses shown are representative of IgG2b and IgGa 
responses obtained. IgGa responses tend to be somewhat less suppressible and to escape 
from suppression somewhat more frequently (1). 
Immunizing carrier-primed animals with DNP on an unrelated carrier molecule, 
in  contrast,  does  not  interfere  with  antibody  production  to  DNP.  KLH-primed 
animals stimulated with DNP-CGG similarly produced normal primary and second- 
ary  anti-hapten  responses,  etc.  (see  Table  I).  Therefore,  the  impaired  anti-DNP 
responses  in  animals immunized sequentially with a  carrier protein  and a  hapten 
(DNP)  conjugated to the same carrier protein are specifically the result of immuni- 
zation with this carrier/hapten-carrier sequence. 
The landmark papers (10,  11) demonstrating the presence of carrier-specific helper 
T  cells  in  carrier-primed  mice also  noted that  the donors  used  for these adoptive 
transfer experiments (surprisingly) failed to respond to haptens presented subsequently 
on the priming carriers. These in situ response failures were later ascribed either to 
impaired anti-hapten memory B cell development in carrier/hapten-carrier  immu- 
nized  animals  or  to  insufficient carrier-specific  helper  T  cell  activity capable  of 
supporting a  primary response to the new hapten presented on the priming carrier. 
Evidence presented below, however, rules out both of these explanations and shows 
directly that anti-hapten responses fail because they are specifically suppressed after 
carrier/hapten-carrier immunization. 
Anti-Hapten Memory B Cells and Carrier-specific Helper T Cells Develop Normally in Carrier/ 
Hapten-Carrier Immunized Mice.  Adoptive transfer studies with a protocol that favors 
detection of relatively minor differences in memory development (7)  show directly 
that hapten-carrier conjugates stimulate normal anti-hapten memory B cell develop- 
ment in carrier/hapten-carrier  immunized mice.  Splenic B  cell populations  (T-de- 
pleted)  from KLH-primed mice immunized with DNP-KLH 3 wk before transfer 
give rise to adoptive anti-DNP memory responses equivalent in magnitude, affinity, 
and isotype representation to control responses produced by memory B cell popula- 
TABLE  II 
Epitope-specific Suppression Does Not Interfere with Anti-Hapten Memory B Cell Development 




--9 wk  --3 wk  Status  Cells transferred:~  IgG2.  lgGl 
gg/ral 
KLH  DNP-KLH  Suppressed  Spleen (T +  B)  32  250 
--  DNP-KLH  Control  Spleen (T +  B)  120  125 
KLH  DNP-KLH  Suppressed  T-depleted spleen (B)  104  300 
--  DNP-KLH  Control  T-depleted spleen (B)  90  125 
100 gg each antigen intraperitoneally on alum. 
* Serum anti-DNP levels measured by RIA 7 d after transfer. 
:~ 107 spleen cells (BALB/c ×  SJL)  or remaining (T-depleted) cells from  107 spleen cells after treatment 
with  monoclonal anti-Thy-l.2  plus complement. T-depleted populations were supplemented with  10  7 
KLH-primed T  cells (as a source of carrier-specific help). Recipients (600  rad irradiated BALB/c) were 
injected intravenously with the indicated cell populations plus 1 /tg aqueous DNP-KLH. 1734  CARRIER-SPECIFIC INDUCTION OF SUPPRESSION 
tions from mice immunized only with DNP-KLH (see Table II). Similarly, IgD+ and 
IgD- memory B cell activity (7) is equivalent in these B cell populations (data not 
shown).  Thus, carrier/hapten-carrier immunization  impairs anti-hapten  memory B 
cell expression rather than development. 
This impairment is not because of interference with carrier-specific help. Carrier/ 
hapten-carrier-immunized animals have ample carrier-specific help to support either 
primary or secondary antibody responses to most of the determinants on the immu- 
nizing conjugate, even though they produce only minimum anti-DNP responses when 
stimulated  with  such  conjugates,  i.e.,  primary  and  secondary anti-CGG  and  anti- 
KLH responses proceed normally in all cases (Table I). Thus, anti-hapten antibody 
production fails in these animals despite the presence and apparently normal potential 
of the two types of lymphocytes currently known to be required for such antibody 
production (anti-hapten memory B and carrier-specific helper T). In other words, this 
response  failure is  caused  by the  induction  of active suppression  rather  than  by a 
deficit of the requisite cells. 
An Epitope-specific Effector Mechanism Mediates the Suppression Induced in Carrier/ Hapten- 
Carrier-immunized Mice.  The specificity of the suppression-effector mechanism is dem- 
onstrated most clearly by the failure of the potential secondary anti-hapten response 
in carrier/hapten-carrier-immunized animals stimulated subsequently with the hap- 
ten on a second (unrelated) carrier molecule. For example (as indicated above), KLH/ 
DNP-KLH-immunized mice stimulated with DNP-CGG produce normal anti-CGG 
primary responses but fail to produce more than a minimum anti-DNP response, and 
CGG/DNP-CGG-immunized mice show a similar specific inability to produce anti- 
DNP antibody when stimulated with DNP-KLH (Table I). Thus, regardless of which 
carrier is used in the carrier/hapten-carrier immunization sequence and which is used 
subsequently to test the specificity of the suppression, the result is the same: the anti- 
DNP  response  is  specifically  suppressed  while  the  antibody  responses  to  carrier 
epitopes proceed normally. 
These findings  rule out  nonspecific suppressive mechanisms  such  as  interference 
with antigen handling, processing, or presentation. In addition, they exclude mecha- 
nisms  that  interfere  with  carrier-specific help  because  these  kinds  of mechanisms 
should either affect responses to all epitopes on the hapten-carrier conjugate equally, 
or they should have a more drastic suppressive effect on the primary responses to the 
carrier epitopes than on the potential secondary responses (to DNP). Therefore, the 
mechanism mediating suppression in carrier/hapten-carrier mice is "epitope-specific" 
in the sense that it selectively suppresses antibody production to one of the epitopes 
(DNP) on a complex antigen. 
Carrier-specific Suppressor T Cells Induce Epitope-specific Suppression.  The specificity of 
the  mechanism  responsible  for inducing  (as  opposed  to  mediating)  suppression  in 
carrier/hapten-carrier-immunized  mice  parallels  the  specificity of the  well-known 
carrier-specific suppressor T  cells  (CTs)  that  are generated by KLH priming  (4,  5) 
and  suppress adoptive or in  vitro responses to DNP on KLH but  not on unrelated 
carriers.  That  is,  DNP-KLH  immunization  induces  suppression  (for anti-DNP  re- 
sponses) in  KLH-primed animals, whereas DNP-CGG immunization does not;  and 
DNP-CGG induces suppression in CGG-primed mice, whereas DNP-KLH does not. 
Furthermore, the overall properties reported for the suppression obtained with KLH- LEONORE  A.  HERZENBERG  AND  TAKESHI  TOKUHISA  1735 
specific CTs foreshadow the properties of epitope-specific suppression  (e.g., selective 
interference with high-affinity anti-hapten antibody production). 
Studies conducted in collaboration with Dr. Masaru Taniguchi (in his laboratory 
at Chiba University, Chiba, Japan) confirm the surprising implications of the above 
findings. These studies show directly that CTs and CTs factors generated and tested 
according to protocols developed by Tada and collaborators (4, 5) regulate antibody 
responses by inducing epitope-specific suppression. That is, KLH-specific CTs trans- 
ferred to nonirradiated recipients challenged immediately after transfer with DNP- 
KLH induce a specific and persistent suppression for IgG antibody responses to DNP. 
Thus,  these recipients  produce  normal  anti-KLH responses  but  show typical sup- 
pressed responses to DNP injected subsequently on KLH or on an unrelated carrier 
(Table III). Soluble KLH-specific suppressor factors induce a similar suppression (12). 
In  a  related  series  of adoptive  co-transfer  studies  (2)  (conducted  in  our  own 
laboratory), we have shown that epitope-specific suppression is difficult to induce or 
demonstrate in irradiated recipients. This is consistent with evidence presented by 
Eardley and Gershon (13) showing that the same carrier-primed T  cells that provide 
help for adoptive responses in irradiated recipients will suppress such responses if co- 
transferred with T cells from an unprimed donor. These peculiar properties of response 
regulation in  "reconstituted" animals probably explain how KLH-primed animals 
can  be  used  as  an  excellent  source  of KLH-specific help  for  adoptive  anti-DNP 
responses to DNP-KLH and yet be induced to suppress in situ anti-DNP responses by 
immunization with this same hapten-carrier conjugate, 
Analysis of the characteristics of the  in  situ  mechanism responsible  for inducing 
epitope-specific  suppression  provide  further  evidence  indicating  that  CTs  act  by 
inducing epitope-specific suppression. For example, studies summarized in Table IV 
show (a)  that carrier-immunization protocols used to generate CTs populations also 
generate the in situ carrier-specific mechanisms that induce epitope-specific suppres- 
sion;  (b)  that  the  "kinetics" of CTs  appearance  match  the  kinetics  of the  in  situ 
suppression-induction  mechanism  (2,  14); and  (c)  that  the  genetic  elements  that 
govern CTs activity (2, 7) also govern in situ suppression induction. 
TABLE  III 
Carrier-specific Suppressor T Cells Induce Epitope-specific Suppression 
KLH  1  o cells 
transferred 
IgG2a antibody  Antigen (weeks)  response (RIA) 
Anti-  Anti-  Anti- 
0  4  8  DNP  KLH  CGG 
None  DNP-KLH  DNP-KLH  120  9  NT* 
None  DNP-KLH  DNP-KLH  DNP-CGG  100  NT  35 
Spleen  DNP-KLH  DNP-KLH  20  8  NT 
Spleen  DNP-KLH  DNP-KLH  DNP-CGG  10  NT  20 
Spleen (T-depleted)  DNP-KLH  DNP-KLH  140  11  NT 
DNP-KLH  DNP-KLH  DNP-CGG  125  NT  39 
Donors  primed  with  100  gg  aqueous  KLH  at  -4  and  -2  wk.  50  ×  106  spleen  cells  transferred 
intravenously to BALB/c (nonirradiated)  recipients; Recipients challenged with  100 #g of each antigen 
at indicated times; Antibody response measured 2 wk after last antigenic stimulation; Anti-DNP response 
is p,g/ml; Anti-KLH is percent secondary response standard serum. 
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Specificity  data  from  previous  CTs  studies  have  generally been  interpreted  as 
indicating that CTs regulate antibody responses by controlling the supply of carrier- 
specific help; however, viewed in retrospect, this evidence is insufficient to distinguish 
a  carrier-specific suppression-effector mechanism from a  carrier-specific suppression- 
induction mechanism coupled with an epitope-specific effector mechanism. Thus, by 
extending  the  earlier  protocols  to  include  examination of  anti-carrier  as  well  as 
antihapten antibody responses  and  by  testing CTs-suppressed  recipients  for  their 
subsequent ability to respond to DNP on an unrelated carrier, we obtained evidence 
that is entirely consistent with the earlier findings but leads to a  strikingly different 
conclusion concerning the role CTs play in regulating responses. 
In sum, we now show definitively  that CTs activity in adoptive assays is functionally 
identical to the activity of the carrier-specific mechanism that induces epitope-specific 
suppression  in  KLH/DNP-KLH-immunized  animals.  Consequently, we  conclude 
that CTs induced when an animal first encounters a carrier protein serve subsequently 
(in situ,  in vitro, or in appropriate adoptive recipients) to induce suppression for new 
epitopes subsequently encountered on that carrier. 
Epitope-specific Suppression Is a General Regulatory Process.  Tables IV and V summarize 
data  from  our  laboratory  and  elsewhere,  demonstrating that  the  epitope-specific 
system regulates antibody production to a  variety of antigens and can be induced by 
widely  different  immunization conditions.  In  essence,  these  studies  (2)  show  that 
varying the  hapten, carrier, age,  or strain of the  animals immunized, the  intervals 
between  carrier  and  hapten-carrier injection, or  the  dose  or  form  of the  injected 
carrier protein has very little effect  on the induction of suppression by the carrier/ 
TAnLE IV 
Epitope-specific  Suppression Is a General Regulatory Process: Immunization  Conditions That Permit 
Suppression Induction by the Carrier/Hapten-Carrier  Sequence 
Parameter examined*  Result 
Carriers  KLH, CGG, OVA, TGAL 






KLH/DNP-KLtt,  then  DNP-KLH 
or DNP-CGG up to 1 yr later 
KLH:  1, 10, or 100/zg on alum 
Alum + B. pertussis, alum alone, CFA, 
aqueous antigen 
1-13 wk  between KLtt  and  DNP- 
KLH 
KLt| immunization at 8 wk to >6 mo 
All effective except when genetically restricted~§ 
All effective; suppression also inducible for re- 
sponses to KLH epitopes§ 
Anti-DNP suppression equally strong 
Strong suppression induced with 100 ~g; weak 
suppression with 10 #g; no suppression with 1 
#g 
B. pertussis with the carrier prevents suppression- 
induction; other adjuvants do not interefere; 
aqueous antigen somewhat better suppression 
induction 
Suppression equally strong with all  intervals; 
<1 wk and >13 wk not tested 
Suppression equally strong at all ages 
* For reference to data cited, please see text. 
Preliminary evidence indicates that suppression  induced with certain carriers is relatively easily overcome 
by subsequent immunization with DNP-CGG or DNP-KLtt.  Primary immunization with DNP coupled 
to these carriers, e.g., sheep erythrocytes (in our hands), tends to induce predominantly IgM and IgGa 
anti-DNP responses rather than the full range of isotype responses induced by DNP conjugates of the 
carriers listed in this table. 
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TAaLE V 
Epitope-specific Suppression  Is a General Regulatory  Process: Genetic and Regulatory  Conditions  That 
Permit Suppression  Induction 
Parameters tested*  Result 
Mouse strains  BALB/c, BAB/14, SJL, SJA,  Suppression  inducible in all strains 
SJL,  ×  BALB/c, C3H, 
C3H.SW, A/J, C57BL/10, 
C57BL/6 
TGAL/TNP-TGAL  in  C3H 
(H-2k) and  C3H.SW (H- 
2b) eongenie mice 
KLH in A/J and C57BL/10 
IR gene control 
Carrier  function genes 






KLH-primed T cells contain- 
ing CTs and CTh activity; 
DNP-KLH to recipients 
DNP-KLH priming in young 
mice "acutely" suppressed 
for Igh-lb allotype 
Suppression stronger in C3H (nonresponders); 
suppression in C3H.SW comparable to sup- 
pression induced by KLH/DNP-KLH 
Specific impairment of suppression induction 
by KLH/DNP-KLH sequence 
Suppression induced for both by KLH/DNP- 
KLH (Igh~-460  exempt) 
Suppression-induction  favored  in  nonirra- 
diated recipients; help favored in irradiated 
recipients 
Epitope-specific suppression induced for Igh- 
lb  anti-DNP and  Igh-lb  anti-KLH  re- 
sponses; suppression  active during midlife 
remission from allotype suppression 
* See text for references. 
hapten-carrier sequence. Only two protocol modifications tested impaired suppression 
induction:  injecting lower carrier-protein doses or injecting Bordetella pertussis  (but not 
complete Freund's adjuvant)  together with the carrier protein. 
Interestingly,  the  carrier/hapten-carrier  sequence  induces  strong  epitope-specific 
suppression for anti-DNP responses in animals carrying an immune response gene (Ir- 
la)  (15),  previously believed  to  prevent  responsiveness to the carrier  molecule;  i.e., 
TGAL/TNP-TGAL  immunization  induces  persistent  suppression  for IgG responses 
to trinitrophenyl  (TNP)  on  KLH or CGG in  C3H  (H-2k, Ir-la)  animals  (4).  Non- 
major histocompatibility complex gene(s)  that specifically interfere with CTs induc- 
tion by carrier immunization (16), in contrast, markedly impair suppression induction 
by the carrier/hapten-carrier sequence, e.g., by KLH/DNP-KLH  in A/J mice (Table 
v). 
Table  V  also  refers  to  studies  presented  in  the  third  publication  in  this  series, t 
demonstrating that the immunization of young allotype-suppressed mice with DNP- 
KLH induces an allotype-restricted, epitope-specific suppression  for Igh-lb allotype 
antibody responses to all determinants on the DNP-KLH molecule. This suppression 
persists  throughout  the  characteristic  midlife  remission  from  allotype  suppression 
during which  normal  Igh-lb antibody responses are produced  to newly  introduced 
antigens. Thus, direct immunization with hapten-carrier conjugates induces epitope- 
specific  suppression  in  an  immunologically  compromised  animal,  and  the  overall 
specificity of the suppression induced reflects the conditions in the regulatory environ- 
ment that led to the induction of suppression. 
Taken together, these various studies demonstrate that epitope-specific suppression 
is  a  broadly occurring  and  robust  regulatory process clearly discernible  within  the 1738  CARRIER-SPECIFIC  INDUCTION OF  SUPPRESSION 
confines of antibody responses commonly taken  as  representative of the  "normal" 
functioning of the immune system. 
Is  Epitope-specific  Regulation  Consistent  with  the  Known  Properties  of  Antibody 
Responses?  The findings presented here, clearcut in themselves, nevertheless appear 
paradoxical when considered within the context of normal secondary (anamnestic) 
antibody  responses.  That  is,  if restimulation  with  an  antigen  leads  to  augmented 
antibody production,  shouldn't  responses  to a  new  hapten  on  the  antigen  also  be 
augmented rather than suppressed; or, conversely, given the antigen-induced presence 
of CTs capable of inducing epitope-specific suppression for antibody responses to new 
determinants presented on a priming antigen, shouldn't CTs also induce suppression 
for responses to the "old" determinants as well? 
The answer  to this  key question  lies in  perhaps  the  most  novel property of the 
epitope-specific system: its ability to provide either stable support or stable suppression 
for individual anti-epitope responses, depending on how it is first induced. That is, if 
the system is induced to support antibody production for a given epitope before CTs 
mature, then that anti-epitope response will be "protected" by the time CTs become 
active. Therefore, the mature CTs population present (after about a week) in carrier- 
primed animals will induce suppression for responses to new determinants introduced 
on  the  priming carrier but  will  not  hamper established  antibody responses  to  the 
epitopes present on the carrier molecule itself. We discuss this point more fully in the 
accompanying publication (1). 
Summary 
The epitope-specific regulatory system selectively controls IgG antibody production 
to the individual (haptenic) determinants on a complex antigen. This system can be 
specifically induced to suppress  primary and  secondary IgG antibody responses to 
dinitrophenyl hapten (DNP) without interfering with antibody responses to epitopes 
on the carrier molecule on which the DNP is presented. Furthermore, once induced, 
it will specifically suppress responses to DNP presented on unrelated carrier molecules. 
Results summarized here obtained using widely different immunization conditions, 
and  a  variety of haptens and carrier molecules indicate that  this regulatory system 
controls antibody production in most T-dependent antibody responses. 
Carrier-specific suppressor  T  cells  (CTs)  that  arise shortly after priming  with  a 
carrier molecule such  as  keyhole limpet  hemocyaninin  (KLH)  induce the epitope- 
specific system to suppress in situ and  adoptive antibody responses to epitopes (e.g., 
DNP) presented subsequently on the priming carrier. These well-known regulatory T 
cells  are  commonly  believed  to  regulate  antibody  production  by  interfering with 
carrier-specific help;  however,  by  repeating  the  original  CTs  transfer experiments 
with  additional  controls  that  define  the  specificity  of the  mechanism  mediating 
suppression in CTs recipients, we show that KLH-specific CTs regulate responses by 
inducing typical isotope-specific suppression for anti-DNP responses when the recip- 
ients  are  immunized  with  DNP-KLH.  Thus,  whether  KLH-primed  animals  are 
immunized directly with DNP-KLH (KLH/DNP-KLH immunization sequence) or 
whether T  cells from these animals are challenged with DNP-KLH in (nonirradiated) 
recipients, anti-DNP responses are persistently suppressed while anti-carrier responses 
proceed normally. 
The aqueous KLH-priming protocols usually used to generate CTs are marginally LEONORE  A.  HERZENBERG  AND TAKESHI TOKUHISA  1739 
more  effective  in  priming  for  in  situ  suppression-induction  than  the  alum  KLH- 
priming protocols commonly used to generate KLH-specific helper T  cells and used 
here in KLH/DNP-KLH  immunizations. Thus, studies presented show that priming 
with  an  antigenic  (carrier)  molecule  simultaneously  prepares  the  animal  for  the 
production of typical secondary (anamnestic)  antibody responses to epitopes on  the 
priming antigen  and  for the  induction  of epitope-specific suppression  for antibody 
production  to determinants presented subsequently on the same antigenic molecule. 
We  discuss  the  mechanism(s)  responsible  for  this  duality  and  its  significance  for 
antibody  responses  in  an  accompanying  publication  that  describes  the  bistable 
regulatory capabilities of the epitope-specific system. 
As indicated in  the  text,  part  of these studies were conducted  in  Dr.  Masaru  Taniguichi's 
laboratory, Chiba University, Chiba, Japan. We were fortunate to be able to collaborate with 
Dr.  Taniguichi  in the series of experiments reported here.  Most of the work reported here, 
however, was conducted in Dr. Leonard A. Herzenberg's laboratory at Stanford. We are also 
fortunate to have had the benefit of Dr. Herzenberg's support, advice, and criticism throughout 
this project. We also thank Dr. Kyoko Hayakawa for helpful scientific contributions to these 
studies, Mr. F. T. Gadus for excellent technical assistance, Ms. Jean Anderson and Ms. Debra 
Parks for editorial help, and Mr. Wayne Moore for computer support that greatly aided the 
preparation of this manuscript. 
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